JNJ — Johnson & Johnson

Johnson & Johnson Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Sales: $24.6 billion, up 7.1% year-over-year despite a 650 basis point headwind from STELARA.
• Full-Year 2025 Sales: $94.2 billion, a 5.3% increase, with U.S. growth at 6.9% and international at 3.4%.
• Net Earnings: Q4 net earnings of $5.1 billion; diluted EPS of $2.10, up from $1.41 a year ago. Full-year net earnings were $26.8 billion, with diluted EPS of $11.30.
• Adjusted Earnings: Q4 adjusted net earnings of $6 billion; adjusted diluted EPS of $2.46, a 21.5% increase compared to Q4 2024. Full-year adjusted net earnings were $26.2 billion, with adjusted diluted EPS of $10.79, up 8.1%.

2. Strategic Updates and Business Highlights

• Business Segments: Continued strong performance across six key areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision.
• Innovative Medicine Growth: Sales of $15.8 billion in Q4, up 7.9%, with significant contributions from DARZALEX (24.1% growth) and Tremfya (65.4% growth).
• MedTech Performance: Sales of $8.8 billion in Q4, up 5.8%, driven by strong growth in cardiovascular (15.2%) and surgical vision (10.8%).
• R&D Investments: Over $32 billion invested in R&D and M&A in 2025, including acquisitions of Intracellular Therapies and Halda Therapeutics.
• Pipeline Progress: 51 approvals and 32 submissions in 2025, with promising results in oncology and immunology.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Expected operational sales growth of 5.7% to 6.7%, with a midpoint of $100 billion. Adjusted operational growth is anticipated at 5.9%.
• Earnings Guidance: Adjusted EPS growth projected at 5.5%, with a range of $11.28 to $11.48. Reported adjusted EPS expected at $11.53.
• Long-Term Growth: Confidence in achieving double-digit growth by the end of the decade, supported by a strong portfolio and pipeline.

4. Challenges and Points of Concern

• STELARA Erosion: Continued decline due to biosimilar competition, impacting overall sales growth.
• Litigation Risks: Ongoing talc-related litigation remains a concern, with potential implications for reserves and company reputation.
• Competitive Pressures: Facing challenges in MedTech, particularly in the electrophysiology market where growth is below market expectations.
• Cost Pressures: Increased tariffs and costs associated with new product launches may impact margins.

5. Notable Q&A Insights

• Strategic Positioning: CEO Joaquin Duato emphasized the company's focus on high-growth areas and the planned separation of the orthopedics business to enhance growth potential.
• Market Confidence: Executives expressed confidence in the pipeline, particularly in oncology and immunology, citing several promising products expected to drive future growth.
• MedTech Outlook: Tim Schmid highlighted expectations for acceleration in MedTech growth in 2026, despite current market challenges.
• Regulatory Developments: Discussion on upcoming regulatory submissions and approvals, particularly for new therapies in oncology and MedTech, indicating a proactive approach to market expansion.

Overall, Johnson & Johnson reported strong financial results for Q4 2025, driven by robust growth across its business segments. The company is optimistic about its future growth trajectory, despite facing challenges related to competition and ongoing litigation.